来源:[1] Guardant 报告 Shield 算法临床读数更新 (https://www.medicaldevice-network.com/news/gu ...)[2] 尽管 Evercore ISI 持积极展望,Guardant Health 股价仍下跌 8% - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)[3] Guardant Health 的 Shield 血液检测显示对结直肠癌有 84% 的灵敏度 - Investing.com (https://www.investing.com/news/stock-market-n ...)